Weekly Docetaxel and Four Weekly Carboplatin in Non-small Cell Lung Cancer Carbo-Tax

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00826852
Recruitment Status : Completed
First Posted : January 22, 2009
Last Update Posted : July 27, 2010
Information provided by:

October 13, 2008
January 22, 2009
July 27, 2010
October 2003
July 2009   (Final data collection date for primary outcome measure)
Efficacy by response rate [ Time Frame: After the 3rd cycle, 6th cycle and at every follow up visit ]
Same as current
Complete list of historical versions of study NCT00826852 on Archive Site
  • Adverse events [ Time Frame: At each visit ]
  • Efficacy by time to progression [ Time Frame: Until the progression of all patients ]
  • Overall survival [ Time Frame: At the end of the study ]
Same as current
Not Provided
Not Provided
Weekly Docetaxel and Four Weekly Carboplatin in Non-small Cell Lung Cancer Carbo-Tax
Phase II Trial of Weekly Docetaxel and Four Weekly Carboplatin Combination in the First-line Treatment of Advanced Non-small Cell Lung Cancer

The purpose of this study is:

  • to assess the efficacy of the combination in terms of Objective (clinical and radiological) Response Rate
  • to assess the time to progression of the disease; assess the safety profile of the combination, and assess the survival time.
Not Provided
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Lung Neoplasms
Drug: docetaxel and carboplatin
weekly docetaxel 30mg/m2 and four weekly carboplatin AUC (Area under curve) 5
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
July 2009
July 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically/cytologically confirmed inoperable locally advanced or metastatic non-small cell lung cancer
  • ECOG Performance Status is 0-2
  • At least one measurable lesion in two dimensions by means of CT scan
  • No brain metastases
  • No prior chemotherapy for this malignancy,
  • Acceptable hematological profile (as defined by a leukocyte count ≥ 3000/mm3, a platelet count ≥ 100.000mm3 and Hb ≥ 9g/100mL), and adequate renal function (as defined by serum creatinine ≤ 1.5mg/dl or creatinine clearance measured in 24 hours urine ≥ 60 mL/min), and hepatic function (as defined by bilirubin ≤ 1.5 x maximum normal value even with hepatic metastasis; transaminases (ALT, AST) ≤ 2.5 x maximum normal value; alkaline phosphatase ≤ 2.5 x maximum normal value, except in case of a bone metastasis)

Exclusion Criteria:

  • Concomitant use of another anti-cancer therapy
  • Chemotherapy, radiotherapy or curative surgery
  • Evidence of intracerebral metastasis
  • Unstable medical condition that makes the patient to take part in a clinical study (congestive heart failure, serious arrhythmia, uncontrolled diabetes mellitus), history of myocardial infarction within last 3 months, massive pleural or peritoneal effusion; or presence of serious uncontrolled infection, diarrhea, ileus, interstitial pneumonia, pulmonary fibrosis.
  • Presence of other tumours different from basal cell carcinoma of the skin, with disease free survival less then 3 years.
  • Pregnancy or breastfeeding. In women of childbearing potential and in men, an adequate contraceptive method must be used
  • Social or psychological condition that render the patient inadequate for the follow-up of the study
  • Contraindication for any of the study drugs (e.g. history of hypersensitivity to any of the ingredients of the study drugs)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sexes Eligible for Study: All
up to 75 Years   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Medical Affairs Study Director, Sanofi aventis
Not Provided
Study Director: Edibe Taylan, MD Sanofi
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP